Zobrazeno 1 - 10
of 83
pro vyhledávání: '"Nathan Singh"'
Autor:
Paolo A. Ascierto, Antonio Avallone, Carlo Bifulco, Sergio Bracarda, Joshua D. Brody, Leisha A. Emens, Robert L. Ferris, Silvia C. Formenti, Omid Hamid, Douglas B. Johnson, Tomas Kirchhoff, Christopher A. Klebanoff, Gregory B. Lesinski, Anne Monette, Bart Neyns, Kunle Odunsi, Chrystal M. Paulos, Daniel J. Powell, Katayoun Rezvani, Brahm H. Segal, Nathan Singh, Ryan J. Sullivan, Bernard A. Fox, Igor Puzanov
Publikováno v:
Journal of Translational Medicine, Vol 21, Iss 1, Pp 1-21 (2023)
Abstract The discovery and development of novel treatments that harness the patient’s immune system and prevent immune escape has dramatically improved outcomes for patients across cancer types. However, not all patients respond to immunotherapy, a
Externí odkaz:
https://doaj.org/article/627c0bedba0a40d4b9dd41c55b9dde62
Autor:
Amanda Heard, Jack H. Landmann, Ava R. Hansen, Alkmini Papadopolou, Yu-Sung Hsu, Mehmet Emrah Selli, John M. Warrington, John Lattin, Jufang Chang, Helen Ha, Martina Haug-Kroeper, Balraj Doray, Saar Gill, Marco Ruella, Katharina E. Hayer, Matthew D. Weitzman, Abby M. Green, Regina Fluhrer, Nathan Singh
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-11 (2022)
Loss of surface CD19 expression by leukemic cells leads to resistance and relapse to CD19-targeted CAR-T therapies. Here the authors show that loss of SPPL3 in malignant B cells results in hyperglycosylation of CD19.
Externí odkaz:
https://doaj.org/article/0f7c94a068e44180b9af36e2164d17d4
Publikováno v:
STAR Protocols, Vol 4, Iss 1, Pp 101954- (2023)
Summary: Several pre-clinical models reveal that chronic chimeric antigen receptor (CAR) stimulation drives a dysfunctional state that mimics in vivo failure. In this protocol, we describe steps to induce T cell dysfunction by persistent and long-ter
Externí odkaz:
https://doaj.org/article/72f6cf4ce538480f98168e1e2380c770
Publikováno v:
International Journal of Emergency Medicine, Vol 14, Iss 1, Pp 1-11 (2021)
Abstract Background Emergency department (ED) visits show a high volatility over time. Therefore, EDs are likely to be crowded at peak-volume moments. ED crowding is a widely reported problem with negative consequences for patients as well as staff.
Externí odkaz:
https://doaj.org/article/75a49da560ba4fe7a1f7eb83d99560d6
Autor:
Ajay Major, Jovian Yu, Navika D. Shukla, Rachel Treitman, Manali K. Kamdar, Bradley M. Haverkos, James Godfrey, Melissa A. Babcook, Timothy J. Voorhees, Sophie G Carlson, Daria Gaut, Caspian Oliai, Jason T. Romancik, Allison Winter, Brian T. Hill, Radhika Bansal, Jose C. Villasboas, Imran A. Nizamuddin, Reem Karmali, Lindsey A. Fitzgerald, Deborah M. Stephens, Priyanka A. Pophali, Asaad Trabolsi, Jonathan H. Schatz, Marie Hu, Veronika Bachanova, Michael J Slade, Nathan Singh, Nausheen Ahmed, Joseph P. McGuirk, Michael R. Bishop, Peter A. Riedell, Justin Kline
Publikováno v:
Blood. 140:1328-1331
Autor:
Armin Ghobadi, Jack H. Landmann, Alun Carter, Matthew L. Cooper, Mehmet Emrah Selli, Jufang Chang, Matthew Baker, Christopher A. Miller, Francesca Ferraro, David Y. Chen, Amanda M. Smith, Taylor A. LaValle, Eric J. Duncavage, Justin Chou, Victor Tam, Joseph M. Benoun, Jenny Nater, Nathalie Scholler, Francesca Milletti, Remus Vezan, Adrian Bot, John M. Rossi, Nathan Singh
Publikováno v:
Blood Advances. 6:5634-5640
Autor:
Alexander B. Kim, Ssu-Yu Chou, Solomon Kang, Eric Kwon, Matthew Inkman, Jeffrey Szymanski, Neal Andruska, Cian Colgan, Jin Zhang, Joanna C Yang, Nathan Singh, Carl DeSelm
Publikováno v:
Blood Advances.
CAR T-cell therapy represents a major advance for hematologic malignancies, with some patients achieving long-term remission. However, the majority of treated patients still die of their disease. A consistent predictor of response is tumor quantity,
Autor:
Ajay Major, Jovian Yu, Navika Shukla, Yan Che, Theodore G Karrison, Rachel Treitman, Manali Kamdar, Bradley M Haverkos, James Godfrey, Melissa A Babcook, Timothy J Voorhees, Sophie Gabrielle Carlson, Daria Gaut, Caspian Oliai, Jason T. Romancik, Allison M Winter, Brian T. Hill, Radhika Bansal, Jose Caetano Villasboas, Imran A. Nizamuddin, Reem Karmali, Lindsey A. Fitzgerald, Deborah M. Stephens, Priyanka A Pophali, Asaad Trabolsi, Jonathan H Schatz, Marie Hu, Veronika Bachanova, Michael Slade, Nathan Singh, Nausheen Ahmed, Joseph P McGuirk, Michael R. Bishop, Peter A. Riedell, Justin Kline
Publikováno v:
Blood Advances.
Checkpoint inhibitor (CPI) therapy with anti-PD-1 antibodies has been associated with mixed outcomes in small cohorts of aggressive B-cell lymphoma patients following CAR T-cell therapy failure. To more definitively define CPI therapy efficacy in thi
Autor:
Andrei Thomas-Tikhonenko, Sarah K. Tasian, Yoseph Barash, Marco Ruella, Kristen W. Lynch, Nathan Singh, Maureen M. O'Brien, Susan R. Rheingold, Deanne M. Taylor, Rawan Shraim, Mukta Asnani, Carolin Schmidt, John Chukinas, Asen Bagashev, David A. Hottman, Mathieu Quesnel-Vallières, Manuel Torres-Diz, Zhiwei Ang, Katharina E. Hayer, Ammar S. Naqvi, Elisabeth Gillespie, Sisi Zheng
Supplementary Data from Modulation of CD22 Protein Expression in Childhood Leukemia by Pervasive Splicing Aberrations: Implications for CD22-Directed Immunotherapies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ab6aeb24bca7462aba4fb3d2d8eb381
https://doi.org/10.1158/2643-3230.22544534.v1
https://doi.org/10.1158/2643-3230.22544534.v1
Autor:
Yangbing Zhao, David M. Barrett, Stephan A. Grupp, Carl H. June, Shuguang Jiang, Jessica Hulitt, Xiaojun Liu, Nathan Singh
Cell size of T cells engineered with lentivirus or RNA.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4758177176a17b51d4fee31c3ed1cb54
https://doi.org/10.1158/2326-6066.22535963
https://doi.org/10.1158/2326-6066.22535963